Hyaluronan-coated extracellular vesicles- A novel link between hyaluronan and cancer

Advances in Cancer Research

Volumn 123, Issue , 2014, Pages 121-148

  Rilla, Kirsi ^a   Siiskonen, Hanna ^a,b   Tammi, Markku ^a   Tammi, Raija ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Biomarker; Cancer; Exosome; Extracellular matrix; Extracellular vesicle; HA synthase; Hyaluronan; Metastasis; Microvesicle; Microvillus

Indexed keywords

BIOLOGICAL MARKER; CELL PROTEIN; CYTOSTATIC AGENT; GELATINASE B; GLUCOSE; HYALURONIC ACID; INTEGRIN; INTERLEUKIN 8; LIPOSOME; MAGNETIC NANOPARTICLE; MICRORNA; MYOSIN; NANOPARTICLE; SCATTER FACTOR; SPHINGOMYELIN; SYNTHETASE; TRASTUZUMAB; VASCULOTROPIN; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CARBOHYDRATE SYNTHESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CELL TYPE; COLON CARCINOMA; ENDOTHELIUM CELL; ENZYME ACTIVITY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; INFLAMMATION; LUNG ADENOCARCINOMA; MACROMOLECULE; MACROPHAGE; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA EFFUSION; MALIGNANT TRANSFORMATION; MELANOMA; MEMBRANE VESICLE; MESENCHYMAL STEM CELL; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERITONEAL FLUID; PERSONALIZED MEDICINE; PLASMA; PLEURA FLUID; PRIORITY JOURNAL; PROSTATE CARCINOMA; SALIVA; SECOND MESSENGER; SQUAMOUS CELL CARCINOMA; SYNOVIAL FLUID; TARGET CELL; THROMBOCYTE; THROMBOSIS; TISSUE REGENERATION; TUMOR GROWTH; TUMOR INVASION; TUMOR VASCULARIZATION; URINE; ANIMAL; CELL MOTION; CHEMISTRY; CONFOCAL MICROSCOPY; DOG; EXOSOME; IMMUNOLOGY; MDCK CELL LINE; METABOLISM; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CELL MEMBRANE; CELL MOVEMENT; DOGS; EXOSOMES; EXTRACELLULAR MATRIX; HUMANS; HYALURONIC ACID; INFLAMMATION; MADIN DARBY CANINE KIDNEY CELLS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904916177     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800092-2.00005-8     Document Type: Chapter

References (141)

1. Aatonen M., Grönholm M., Siljander P.R. Platelet-derived microvesicles: Multitalented participants in intercellular communication. Seminars in Thrombosis and Hemostasis 2012, 38:102-113.
2. Akao Y., Iio A., Itoh T., Noguchi S., Itoh Y., Ohtsuki Y., et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Molecular Therapy 2011, 19:395-399.
3. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nature Cell Biology 2008, 10:619-624.
4. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. Journal of Experimental Medicine 2002, 195:1303-1316.
5. Angelucci A., D'Ascenzo S., Festuccia C., Gravina G.L., Bologna M., Dolo V., et al. Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clinical and Experimental Metastasis 2000, 18:163-170.
6. Anttila M.A., Tammi R.H., Tammi M.I., Syrjänen K.J., Saarikoski S.V., Kosma V.M. High levels of stromal HA predict poor disease outcome in epithelial ovarian cancer. Cancer Research 2000, 60:150-155.
7. Arpicco S., Lerda C., Dalla Pozza E., Costanzo C., Tsapis N., Stella B., et al. Hyaluronic acid-coated liposomes for active targeting of gemcitabine. European Journal of Pharmaceutics and Biopharmaceutics 2013, 85:373-380.
8. Auvinen P.K., Parkkinen J.J., Johansson R.T., Ågren U.M., Tammi R.H., Eskelinen M.J., et al. Expression of HA in benign and malignant breast lesions. International Journal of Cancer 1997, 74:477-481.
9. Auvinen P., Rilla K., Tumelius R., Tammi M., Sironen R., Soini Y., et al. HA synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Research and Treatment 2014, 143:277-286.
10. Auvinen P., Tammi R., Kosma V.M., Sironen R., Soini Y., Mannermaa A., et al. Increased HA content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. International Journal of Cancer 2013, 132:531-539.
11. Auvinen P., Tammi R., Parkkinen J., Tammi M., Ågren U., Johansson R., et al. HA in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. American Journal of Pathology 2000, 156:529-536.
12. Bard M.P., Hegmans J.P., Hemmes A., Luider T.M., Willemsen R., Severijnen L.A., et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. American Journal of Respiratory Cell and Molecular Biology 2004, 31:114-121.
13. Bhatnagar S., Shinagawa K., Castellino F.J., Schorey J.S. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 2007, 110:3234-3244.
14. Camussi G., Deregibus M.C., Bruno S., Cantaluppi V., Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney International 2010, 78:838-848.
15. Camussi G., Deregibus M.C., Bruno S., Grange C., Fonsato V., Tetta C. Exosome/microvesicle-mediated epigenetic reprogramming of cells. American Journal of Cancer Research 2011, 1:98-110.
16. Cassara D., Ginestra A., Dolo V., Miele M., Caruso G., Lucania G., et al. Modulation of vesicle shedding in 8701 BC human breast carcinoma cells. Journal of Submicroscopic Cytology and Pathology 1998, 30:45-53.
17. Ciravolo V., Huber V., Ghedini G.C., Venturelli E., Bianchi F., Campiglio M., et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. Journal of Cellular Physiology 2012, 227:658-667.
18. Collet G., Grillon C., Nadim M., Kieda C. Trojan horse at cellular level for tumor gene therapies. Gene 2013, 525:208-216.
19. Contiero P., Berrino F., Tagliabue G., Mastroianni A., Di Mauro M.G., Fabiano S., et al. Fasting blood glucose and long-term prognosis of non-metastatic breast cancer: A cohort study. Breast Cancer Research and Treatment 2013, 138:951-959.
20. Creaney J., Dick I.M., Segal A., Musk A.W., Robinson B.W. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer 2013, 82:491-498.
21. Del Conde I., Bharwani L.D., Dietzen D.J., Pendurthi U., Thiagarajan P., Lopez J.A. Microvesicle-associated tissue factor and Trousseau's syndrome. Journal of Thrombosis and Haemostasis 2007, 5:70-74.
22. Diamant M., Nieuwland R., Pablo R.F., Sturk A., Smit J.W., Radder J.K. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002, 106:2442-2447.
23. Dolo V., D'Ascenzo S., Violini S., Pompucci L., Festuccia C., Ginestra A., et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clinical and Experimental Metastasis 1999, 17:131-140.
24. Dragovic R.A., Gardiner C., Brooks A.S., Tannetta D.S., Ferguson D.J., Hole P., et al. Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis. Nanomedicine 2011, 7:780-788.
25. El-Dakdouki M.H., Xia J., Zhu D.C., Kavunja H., Grieshaber J., O'Reilly S., et al. Assessing the in vivo efficacy of doxorubicin loaded HA nanoparticles. ACS Applied Materials & Interfaces 2013, 8:697-705.
26. Faure J., Lachenal G., Court M., Hirrlinger J., Chatellard-Causse C., Blot B., et al. Exosomes are released by cultured cortical neurones. Molecular and Cellular Neuroscience 2006, 31:642-648.
27. Friedl P., Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Reviews. Cancer 2003, 3:362-374.
28. Galindo-Hernandez O., Villegas-Comonfort S., Candanedo F., Gonzalez-Vazquez M.C., Chavez-Ocana S., Jimenez-Villanueva X., et al. Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients. Archives of Medical Research 2013, 44:208-214.
29. Ginestra A., La Placa M.D., Saladino F., Cassara D., Nagase H., Vittorelli M.L. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Research 1998, 18:3433-3437.
30. Ginestra A., Miceli D., Dolo V., Romano F.M., Vittorelli M.L. Membrane vesicles in ovarian cancer fluids: A new potential marker. Anticancer Research 1999, 19:3439-3445.
31. Ginestra A., Monea S., Seghezzi G., Dolo V., Nagase H., Mignatti P., et al. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. Journal of Biological Chemistry 1997, 272:17216-17222.
32. Gould S.J., Raposo G. As we wait: Coping with an imperfect nomenclature for extracellular vesicles. Journal of Extracellular Vesicles 2013, 2:1-3. 10.3402/jev.v2i0.20389.
33. Graner M.W., Alzate O., Dechkovskaia A.M., Keene J.D., Sampson J.H., Mitchell D.A., et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB Journal 2009, 23:1541-1557.
34. Graves L.E., Ariztia E.V., Navari J.R., Matzel H.J., Stack M.S., Fishman D.A. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Research 2004, 64:7045-7049.
35. Hale J.E., Wuthier R.E. The mechanism of matrix vesicle formation. Studies on the composition of chondrocyte microvilli and on the effects of microfilament-perturbing agents on cellular vesiculation. Journal of Biological Chemistry 1987, 262:1916-1925.
36. Hamada J., Ren J., Hosokawa M. Malignant progression of a weakly malignant rat mammary tumor cell line, ER-1, by tumor microenvironmental factors. Medical Electron Microscopy 1999, 32:87-93.
37. Hascall V.C., Majors A.K., De La Motte C.A., Evanko S.P., Wang A., Drazba J.A., et al. Intracellular HA: A new frontier for inflammation?. Biochimica et Biophysica Acta 2004, 1673:3-12.
38. Heijnen H.F., Schiel A.E., Fijnheer R., Geuze H.J., Sixma J.J. Activated platelets release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999, 94:3791-3799.
39. Hiltunen E.L., Anttila M., Kultti A., Ropponen K., Penttinen J., Yliskoski M., et al. Elevated HA concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Research 2002, 62:6410-6413.
40. Hong B.S., Cho J.H., Kim H., Choi E.J., Rho S., Kim J., et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 2009, 10:556.
41. Huber V., Fais S., Iero M., Lugini L., Canese P., Squarcina P., et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: Role in immune escape. Gastroenterology 2005, 128:1796-1804.
42. Hulsmans M., Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovascular Research 2013, 100:7-18.
43. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S., et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death and Differentiation 2008, 15:80-88.
44. Janowska-Wieczorek A., Marquez-Curtis L.A., Wysoczynski M., Ratajczak M.Z. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2006, 46:1199-1209.
45. Janowska-Wieczorek A., Wysoczynski M., Kijowski J., Marquez-Curtis L., Machalinski B., Ratajczak J., et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. International Journal of Cancer 2005, 113:752-760.
46. Jiang D., Liang J., Noble P.W. HA in tissue injury and repair. Annual Review of Cell and Developmental Biology 2007, 23:435-461.
47. Jokela T.A., Jauhiainen M., Auriola S., Kauhanen M., Tiihonen R., Tammi M.I., et al. Mannose inhibits HA synthesis by down-regulation of the cellular pool of UDP-N-acetylhexosamines. Journal of Biological Chemistry 2008, 283:7666-7673.
48. Josefsson A., Adamo H., Hammarsten P., Granfors T., Stattin P., Egevad L., et al. Prostate cancer increases HA in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome. American Journal of Pathology 2011, 179:1961-1968.
49. Jung T., Castellana D., Klingbeil P., Cuesta Hernandez I., Vitacolonna M., Orlicky D.J., et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 2009, 11:1093-1105.
50. Kalra H., Simpson R.J., Ji H., Aikawa E., Altevogt P., Askenase P., et al. Vesiclepedia: A compendium for extracellular vesicles with continuous community annotation. PLoS Biology 2012, 10:e1001450.
51. Kang L., Lantier L., Kennedy A., Bonner J.S., Mayes W.H., Bracy D.P., et al. HA accumulates with high-fat feeding and contributes to insulin resistance. Diabetes 2013, 62:1888-1896.
52. Karjalainen J.M., Tammi R.H., Tammi M.I., Eskelinen M.J., Ågren U.M., Parkkinen J.J., et al. Reduced level of CD44 and HA associated with unfavorable prognosis in clinical stage I cutaneous melanoma. American Journal of Pathology 2000, 157:957-965.
53. Kim D.K., Kang B., Kim O.Y., Choi D.S., Lee J., Kim S.R., et al. EVpedia: An integrated database of high-throughput data for systemic analyses of extracellular vesicles. Journal of Extracellular Vesicles 2013, 2:1-7. 10.3402/jev.v2i0.20384.
54. Kim C.W., Lee H.M., Lee T.H., Kang C., Kleinman H.K., Gho Y.S. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Research 2002, 62:6312-6317.
55. Kim H.K., Song K.S., Park Y.S., Kang Y.H., Lee Y.J., Lee K.R., et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. European Journal of Cancer 2003, 39:184-191.
56. Kim J.W., Wieckowski E., Taylor D.D., Reichert T.E., Watkins S., Whiteside T.L. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clinical Cancer Research 2005, 11:1010-1020.
57. Kosunen A., Ropponen K., Kellokoski J., Pukkila M., Virtaniemi J., Valtonen H., et al. Reduced expression of HA is a strong indicator of poor survival in oral squamous cell carcinoma. Oral Oncology 2004, 40:257-263.
58. Kultti A., Pasonen-Seppänen S., Jauhiainen M., Rilla K.J., Kärnä R., Pyoriä E., et al. 4-Methylumbelliferone inhibits HA synthesis by depletion of cellular UDP-glucuronic acid and downregulation of HA synthase 2 and 3. Experimental Cell Research 2009, 315:1914-1923.
59. Kultti A., Rilla K., Tiihonen R., Spicer A.P., Tammi R.H., Tammi M.I. HA synthesis induces microvillus-like cell surface protrusions. Journal of Biological Chemistry 2006, 281:15821-15828.
60. Lamparski H.G., Metha-Damani A., Yao J.Y., Patel S., Hsu D.H., Ruegg C., et al. Production and characterization of clinical grade exosomes derived from dendritic cells. Journal of Immunological Methods 2002, 270:211-226.
61. Lance R.S., Drake R.R., Troyer D.A. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Expert Review of Anticancer Therapy 2011, 11:1341-1343.
62. Lau C.S., Wong D.T. Breast cancer exosome-like microvesicles and salivary gland cells interplay alters salivary gland cell-derived exosome-like microvesicles in vitro. PLoS One 2012, 7:e33037.
63. Lee W.R., Laurie J., Townsend A.L. Fine structure of a radiation-induced osteogenic sarcoma. Cancer 1975, 36:1414-1425.
64. Li J., Zhang Y., Liu Y., Dai X., Li W., Cai X., et al. Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. Journal of Biological Chemistry 2013, 288:23586-23596.
65. Liao C.F., Lin S.H., Chen H.C., Tai C.J., Chang C.C., Li L.T., et al. CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells. Molecular Medicine 2012, 18:1269-1280.
66. Lima L.G., Chammas R., Monteiro R.Q., Moreira M.E., Barcinski M.A. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Letters 2009, 283:168-175.
67. Lima L.G., Leal A.C., Vargas G., Porto-Carreiro I., Monteiro R.Q. Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thrombosis Research 2013, 132:450-456.
68. Lima L.G., Oliveira A.S., Campos L.C., Bonamino M., Chammas R., Werneck C., et al. Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thrombosis and Haemostasis 2011, 106:712-723.
69. Lipponen P., Aaltomaa S., Tammi R., Tammi M., Ågren U., Kosma V.M. High stromal HA level is associated with poor differentiation and metastasis in prostate cancer. European Journal of Cancer 2001, 37:849-856.
70. Lo Cicero A., Majkowska I., Nagase H., Di Liegro I., Troeberg L. Microvesicles shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain aggrecanase activity. Matrix Biology 2012, 31:229-233.
71. Lokeshwar V.B., Rubinowicz D., Schroeder G.L., Forgacs E., Minna J.D., Block N.L., et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. Journal of Biological Chemistry 2001, 276:11922-11932.
72. Lötvall J., Rajendran L., Gho Y.S., Thery C., Wauben M., Raposo G., et al. The launch of Journal of Extracellular Vesicles (JEV), the official journal of the International Society for Extracellular Vesicles-About microvesicles, exosomes, ectosomes and other extracellular vesicles. Journal of Extracellular Vesicles 2012, 1:1-2. 10.3402/jev.v1i0.18514.
73. Lukoschek M., Addicks K. Histologic, morphometric study of the human synovial membrane. Zeitschrift für Orthopädie und Ihre Grenzgebiete 1991, 129:136-140.
74. Marleau A.M., Chen C.S., Joyce J.A., Tullis R.H. Exosome removal as a therapeutic adjuvant in cancer. Journal of Translational Medicine 2012, 10:134.
75. Martins V.R., Dias M.S., Hainaut P. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Current Opinion in Oncology 2013, 25:66-75.
76. Mathivanan S., Simpson R.J. ExoCarta: A compendium of exosomal proteins and RNA. Proteomics 2009, 9:4997-5000.
77. McConnell R.E., Higginbotham J.N., Shifrin D.A., Tabb D.L., Coffey R.J., Tyska M.J. The enterocyte microvillus is a vesicle-generating organelle. Journal of Cell Biology 2009, 185:1285-1298.
78. Meng Y., Kang S., Fishman D.A. Lysophosphatidic acid stimulates Fas ligand microvesicle release from ovarian cancer cells. Cancer Immunology, Immunotherapy 2005, 54:807-814.
79. Millimaggi D., Mari M., D'Ascenzo S., Carosa E., Jannini E.A., Zucker S., et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007, 9:349-357.
80. Mine S., Okada Y., Kawahara C., Tabata T., Tanaka Y. Serum HA concentration as a marker of angiopathy in patients with diabetes mellitus. Endocrine Journal 2006, 53:761-766.
81. Morello M., Minciacchi V.R., de Candia P., Yang J., Posadas E., Kim H., et al. Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle 2013, 12:3526-3536.
82. Mu W., Rana S., Zoller M. Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia 2013, 15:875-887.
83. Müller G. Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. Diabetes, Metabolic Syndrome and Obesity 2012, 5:247-282.
84. Mutsaers S.E. The mesothelial cell. International Journal of Biochemistry and Cell Biology 2004, 36:9-16.
85. Nakazawa H., Yoshihara S., Kudo D., Morohashi H., Kakizaki I., Kon A., et al. 4-Methylumbelliferone, a HA synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemotherapy and Pharmacology 2006, 57:165-170.
86. Nykopp T.K., Rilla K., Sironen R., Tammi M.I., Tammi R.H., Hämäläinen K., et al. Expression of HA synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: Inverse correlation between HYAL1 and HA content. BMC Cancer 2009, 9:143.
87. Nykopp T.K., Rilla K., Tammi M.I., Tammi R.H., Sironen R., Hämäläinen K., et al. HA synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of HA in endometrioid endometrial carcinoma. BMC Cancer 2010, 10:512.
88. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine 2012, 18:883-891.
89. Peng P., Yan Y., Keng S. Exosomes in the ascites of ovarian cancer patients: Origin and effects on anti-tumor immunity. Oncology Reports 2011, 25:749-762.
90. Pienimäki J.P., Rilla K., Fülop C., Sironen R.K., Karvinen S., Pasonen S., et al. Epidermal growth factor activates HA synthase 2 in epidermal keratinocytes and increases pericellular and intracellular HA. Journal of Biological Chemistry 2001, 276:20428-20435.
91. Pirinen R., Tammi R., Tammi M., Hirvikoski P., Parkkinen J.J., Johansson R., et al. Prognostic value of HA expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. International Journal of Cancer 2001, 95:12-17.
92. Polasek J. The appearance of multivesicular structures during platelet activation as observed by scanning electron microscopy. Thrombosis Research 1982, 28:433-437.
93. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
94. Qu C., Rilla K., Tammi R., Tammi M., Kröger H., Lammi M.J. Extensive CD44-dependent HA coats on human bone marrow-derived mesenchymal stem cells produced by HA synthases HAS1, HAS2 and HAS3. International Journal of Biochemistry and Cell Biology 2014, 48C:45-54.
95. Rabinowits G., Gercel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: A diagnostic marker for lung cancer. Clinical Lung Cancer 2009, 10:42-46.
96. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., et al. B lymphocytes secrete antigen-presenting vesicles. Journal of Experimental Medicine 1996, 183:1161-1172.
97. Raposo G., Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. Journal of Cell Biology 2013, 200:373-383.
98. Reis L.A., Borges F.T., Simoes M.J., Borges A.A., Sinigaglia-Coimbra R., Schor N. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. PLoS One 2012, 7:e44092.
99. Renzulli J.F., Del Tatto M., Dooner G., Aliotta J., Goldstein L., Dooner M., et al. Microvesicle induction of prostate specific gene expression in normal human bone marrow cells. Journal of Urology 2010, 184:2165-2171.
100. Ricciardelli C., Ween M.P., Lokman N.A., Tan I.A., Pyragius C.E., Oehler M.K. Chemotherapy-induced HA production: A novel chemoresistance mechanism in ovarian cancer. BMC Cancer 2013, 13:476.
101. Rilla K., Oikari S., Jokela T.A., Hyttinen J.M., Kärnä R., Tammi R.H., et al. HA synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3. Journal of Biological Chemistry 2013, 288:5973-5983.
102. Rilla K., Pasonen-Seppänen S., Deen A.J., Koistinen V.V., Wojciechowski S., Oikari S., et al. HA production enhances shedding of plasma membrane-derived microvesicles. Experimental Cell Research 2013, 319:2006-2018.
103. Rilla K., Pasonen-Seppänen S., Kärnä R., Karjalainen H.M., Törrönen K., Koistinen V., et al. HAS3-induced accumulation of HA in 3D MDCK cultures results in mitotic spindle misorientation and disturbed organization of epithelium. Histochemistry and Cell Biology 2012, 137:153-164.
104. Rilla K., Siiskonen H., Spicer A.P., Hyttinen J.M., Tammi M.I., Tammi R.H. Plasma membrane residence of HA synthase is coupled to its enzymatic activity. Journal of Biological Chemistry 2005, 280:31890-31897.
105. Rilla K., Tiihonen R., Kultti A., Tammi M., Tammi R. Pericellular HA coat visualized in live cells with a fluorescent probe is scaffolded by plasma membrane protrusions. Journal of Histochemistry and Cytochemistry 2008, 56:901-910.
106. Ropponen K., Tammi M., Parkkinen J., Eskelinen M., Tammi R., Lipponen P., et al. Tumor cell-associated HA as an unfavorable prognostic factor in colorectal cancer. Cancer Research 1998, 58:342-347.
107. Sabatier F., Darmon P., Hugel B., Combes V., Sanmarco M., Velut J.G., et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002, 51:2840-2845.
108. Sabin K., Kikyo N. Microvesicles as mediators of tissue regeneration. Translational Research 2014, 163(4):286-295.
109. Safaei R., Larson B.J., Cheng T.C., Gibson M.A., Otani S., Naerdemann W., et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Molecular Cancer Therapeutics 2005, 4:1595-1604.
110. Sainio A., Jokela T., Tammi M.I., Järveläinen H. Hyperglycemic conditions modulate connective tissue reorganization by human vascular smooth muscle cells through stimulation of HA synthesis. Glycobiology 2010, 20:1117-1126.
111. Schneider A., Simons M. Exosomes: Vesicular carriers for intercellular communication in neurodegenerative disorders. Cell and Tissue Research 2013, 352:33-47.
112. Semenza G.L. Tumor metabolism: Cancer cells give and take lactate. Journal of Clinical Investigation 2008, 118:3835-3837.
113. Shedden K., Xie X.T., Chandaroy P., Chang Y.T., Rosania G.R. Expulsion of small molecules in vesicles shed by cancer cells: Association with gene expression and chemosensitivity profiles. Cancer Research 2003, 63:4331-4337.
114. Siiskonen H., Poukka M., Tyynelä-Korhonen K., Sironen R., Pasonen-Seppänen S. Inverse expression of hyaluronidase 2 and HA synthases 1-3 is associated with reduced HA content in malignant cutaneous melanoma. BMC Cancer 2013, 13:181.
115. Silva J., Garcia V., Rodriguez M., Compte M., Cisneros E., Veguillas P., et al. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes, Chromosomes & Cancer 2012, 51:409-418.
116. Sironen R.K., Tammi M., Tammi R., Auvinen P.K., Anttila M., Kosma V.M. HA in human malignancies. Experimental Cell Research 2011, 317:383-391.
117. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology 2008, 10:1470-1476.
118. Sundström G., Dahl I.M., Hultdin M., Lundström B., Wahlin A., Engström-Laurent A. Bone marrow HA distribution in patients with acute myeloid leukemia. Medical Oncology 2005, 22:71-78.
119. Svensson K.J., Kucharzewska P., Christianson H.C., Skold S., Lofstedt T., Johansson M.C., et al. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:13147-13152.
120. Szczepanski M.J., Szajnik M., Welsh A., Whiteside T.L., Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011, 96:1302-1309.
121. Tammi R.H., Passi A.G., Rilla K., Karousou E., Vigetti D., Makkonen K., et al. Transcriptional and post-translational regulation of HA synthesis. FEBS Journal 2011, 278:1419-1428.
122. Tavoosidana G., Ronquist G., Darmanis S., Yan J., Carlsson L., Wu D., et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:8809-8814.
123. Tetta C., Ghigo E., Silengo L., Deregibus M.C., Camussi G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine 2013, 44(1):11-19. 10.1007/s12020-012-9839-0.
124. Thery C., Zitvogel L., Amigorena S. Exosomes: Composition, biogenesis and function. Nature Reviews. Immunology 2002, 2:569-579.
125. Tian T., Wang Y., Wang H., Zhu Z., Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. Journal of Cellular Biochemistry 2010, 111:488-496.
126. Toole B.P., Hascall V.C. HA and tumor growth. American Journal of Pathology 2002, 161:745-747.
127. Toole B.P., Slomiany M.G. HA: A constitutive regulator of chemoresistance and malignancy in cancer cells. Seminars in Cancer Biology 2008, 18:244-250.
128. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology 2007, 9:654-659.
129. Valenti R., Huber V., Filipazzi P., Pilla L., Sovena G., Villa A., et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Research 2006, 66:9290-9298.
130. van Niel G., Raposo G., Candalh C., Boussac M., Hershberg R., Cerf-Bensussan N., et al. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001, 121:337-349.
131. Vangara K.K., Liu J.L., Palakurthi S. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer. Anticancer Research 2013, 33:2425-2434.
132. Varadi T., Mersich T., Auvinen P., Tammi R., Tammi M., Salamon F., et al. Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of HA. Journal of Histochemistry and Cytochemistry 2012, 60:567-575.
133. Vickers K.C., Remaley A.T. Lipid-based carriers of microRNAs and intercellular communication. Current Opinion in Lipidology 2012, 23:91-97.
134. White J.G. Effects of an ionophore, A23187, on the surface morphology of normal erythrocytes. American Journal of Pathology 1974, 77:507-518.
135. Wolf P. The nature and significance of platelet products in human plasma. British Journal of Haematology 1967, 13:269-288.
136. Xiao D., Ohlendorf J., Chen Y., Taylor D.D., Rai S.N., Waigel S., et al. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 2012, 7:e46874.
137. Yang M., Chen J., Su F., Yu B., Su F., Lin L., et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Molecular Cancer 2011, 10:117.
138. Yeo T.K., Nagy J.A., Yeo K.T., Dvorak H.F., Toole B.P. Increased HA at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. American Journal of Pathology 1996, 148:1733-1740.
139. Yoshida H., Miyazaki S., Yumoto T. Matrix vesicles in bone tumors. Ultrastructural analysis and their significance in neoplastic bone formation. Acta Pathologica Japonica 1991, 41:610-617.
140. Yu J.L., May L., Lhotak V., Shahrzad S., Shirasawa S., Weitz J.I., et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 2005, 105:1734-1741.
141. Zu Y., Sidhu G.S., Wieczorek R., Cassai N.D. Ultrastructurally "invasive" microvilli in an aggressively metastasizing biphasic malignant mesothelioma. Ultrastructural Pathology 2002, 26:403-409.